CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

Feasibility and Efficacy of CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs: A Pilot Pragmatic Trial

Pilot pragmatic trial using an implementation science approach to determine the feasibility of a CYP2D6-guided opioid prescribing for patients undergoing elective VHRs compared to usual care. Assess the efficacy (PROMIS Pain Intensity and Hernia-Related QOL) of a CYP2D6-guided opioid prescribing approach for patients undergoing elective VHRs.

Inclusion Criteria:

• > 18 years age undergoing a ventral hernia repair (VHR) ≥1.5 cm in diameter with mesh.

Exclusion Criteria:

• ventral hernia <1.5 cm
• primary ventral hernia repair (VHR) without a mesh
• emergency operative procedure
• receiving chronic opioid therapy (defined as use of opioids on most days for >3 months)
• allergy to opioids
• women of childbearing potential who have a positive pregnancy result as part of their standard pre-surgical workup